文献速递前列腺癌

直肠水凝胶间隔物在前列腺癌放疗后长期肠道生活质量的前瞻性汇总评估

Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life.
PubMed 文献 · BJU Int · 2020-06-29

该研究汇总了接受前列腺癌放疗伴或不伴直肠水凝胶间隔物的患者,评估长期肠道相关生活质量。结果显示,使用间隔物与长期肠道生活质量下降较少相关,且这种获益在长期随访中得以保持。

要点

  • 使用直肠间隔物与长期肠道生活质量下降较少相关。
  • 长期随访中,无间隔物组肠道生活质量临床显著下降的比例更高。
  • 间隔物使用与便急、稀便及排便相关困扰较少相关。

核心结论

  • 在前列腺癌放疗后长达5年的汇总分析中,使用直肠间隔物与肠道生活质量的保持相关,且该获益在长期随访中得以维持。

研究设计与样本

  • 汇总了一项随机多机构试验中215例接受放疗(伴或不伴水凝胶间隔物)且有生活质量终点的患者,与单机构前瞻性收集的165例非随机患者(伴或不伴间隔物)。
  • 共评估380例男性(64%使用间隔物,36%未使用),其中199例随访超过24个月[中位(范围)39.5(31-71.4)个月]有生活质量数据。

主要发现

  • 使用间隔物与长期肠道生活质量平均下降较少相关(对照组89.4,间隔物组94.7),>24个月时组间差异达到MID阈值(肠道评分自基线变化:对照组=-5.1,间隔物组=0.3,差异=-5.4;P<0.001)。
  • 随时间评估,无间隔物者更可能出现肠道生活质量MIDx1(5分)下降(P=0.01)。
  • 长期随访时,MIDx1在无间隔物组为36% vs 间隔物组14%(P<0.001;OR 3.5,95%CI 1.7-6.9),MIDx2为19% vs 6%(P=0.008;OR 3.6,95%CI 1.4-9.1)。
  • 使用间隔物与便急较少(P=0.002)、稀便较少(P=0.009)以及便急困扰较少(P=0.007)和排便频率困扰较少(P=0.009)相关。

关键数值与推荐

  • 肠道领域最小重要差异(MID)相对于治疗前基线的比例采用重复测量逻辑模型检验,预设临床显著下降阈值(≥5相当于MIDx1,≥10相当于MIDx2)。

临床怎么用

  • 对于接受前列腺癌放疗的患者,使用直肠水凝胶间隔物可能有助于长期保持肠道生活质量。

局限性

  • 研究为汇总分析,包含随机试验患者与非随机单机构患者,可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term bowel-associated quality of life (QOL) in men after radiotherapy (RT) for prostate cancer with and without the use of rectal hydrogel spacer. PATIENTS AND METHODS: The patients' QOL was examined using the Expanded Prostate Cancer Index Composite (EPIC) and mean changes from baseline in EPIC domains were evaluated. A total of 215 patients from a randomised multi-institutional trial of RT, with or without hydrogel spacer, with a QOL endpoint were pooled with 165 non-randomised patients from a single institution with prospective QOL collection in patients with or without hydrogel spacer. The proportions of men with minimally important differences (MIDs) relative to pre-treatment baseline in the bowel domain were tested using repeated measure logistic models with a pre-specified threshold for clinically significant declines (≥5 equivalent to MIDx1 and ≥10 equivalent to MIDx2). RESULTS: A total of 380 men were evaluated (64% with spacer and 36% without) with QOL data being available for 199 men with >24 months of follow-up [median (range) 39.5 (31-71.4) months]. Treatment with spacer was associated with less decline in average long-term bowel QOL (89.4 for control and 94.7 for spacer) with differences at >24 months meeting the threshold of a MID difference between cohorts (bowel score difference from baseline: control = -5.1, spacer = 0.3, difference = -5.4; P < 0.001). When evaluated over time men without spacer were more likely to have MIDx1 (5 points) declines in bowel QOL (P = 0.01). At long-term follow-up MIDx1 was 36% without spacer vs 14% with spacer (P <0.001; odds ratio [OR] 3.5, 95% CI 1.7-6.9) while MIDx2 was seen in 19% vs 6% (P = 0.008; OR 3.6, 95% CI 1.4-9.1). The use of spacer was associated with less urgency with bowel movements (P = 0.002) and fewer loose stools (P = 0.009), as well as less bother with urgency (P = 0.007) and frequency of bowel movements (P = 0.009). CONCLUSIONS: In this pooled analysis of QOL after prostate RT with up to 5 years of follow-up, use of a rectal spacer was associated with preservation of bowel QOL. This QOL benefit was preserved with long-term follow-up.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Seymour ZA, Hamstra DA, Daignault-Newton S, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. BJU Int. 2020. PMID: 32333714. doi:10.1111/bju.15097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。